Found 16 matching trials
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma PHASE2 This study was designed to determine the effect of jaundice on the ability ...
Show More Location
Multiple Locations
Learn More & Join Trial
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer PHASE2 An open, dose-ranging, multiple dose, multi-centre study in patients with S...
Show More Location
Multiple Locations
Learn More & Join Trial
Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer PHASE2 This study was designed to investigate the antibody response generated by a...
Show More Location
Glasgow Royal Infirmary
Learn More & Join Trial
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer PHASE3 RATIONALE: Vaccines may make the body build an immune response to kill tumo...
Show More Location
Jonsson Comprehensive Cancer Center, UCLA
Learn More & Join Trial
A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer PHASE2 This study was designed to investigate the safety and tolerance of three do...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma PHASE3 This study will test whether the G17DT Immunogen, when administered in comb...
Show More Location
Multiple Locations
Learn More & Join Trial
Effect of G17DT in Patients With Stage II/III Colorectal Cancer PHASE2 This Phase 2 study was an open label, single-center 18-week study to compar...
Show More Location
Multiple Locations
Learn More & Join Trial
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma PHASE2 This study was designed to evaluate the ability for G17DT to slow or arrest...
Show More Location
Multiple Locations
Learn More & Join Trial
An Open Label Study to Evaluate G17DT Compared to Gemcitabine PHASE3 In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order...
Show More Location
Multiple Locations
Learn More & Join Trial
Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. PHASE2 Pancreatic, gastric, and colorectal cancers have all been shown to overexpr...
Show More Location
University Hospital, Queen's Medical Centre
Learn More & Join Trial